We have not only demonstrated that the acquired resistance to ganetespib in KRAS mutant NSCLC is due to the hyperactivation of critical ERK1/2-p90RSK-mTOR signaling arc and subsequent bypass of G2-M checkpoint arrest [274,275]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.